Can a Ketogenic Diet Help Schizophrenia and Psychosis? What the Emerging Research Shows

A growing body of research, including a landmark international expert consensus published in early 2026, is challenging the long-held assumption that schizophrenia and psychosis are purely lifelong, biologically fixed conditions manageable only through medication. This article explores what that emerging research actually shows — drawing on the most recent peer-reviewed studies — and what it might mean for individuals and families seeking a broader path forward.

For Decades, the Model Has Been Narrow

Modern psychiatry has traditionally focused on pharmacological intervention — aiming to reduce symptoms such as hallucinations, delusions, and disordered thinking through medication. While these treatments can be essential and life-changing for many people, they rarely address underlying causes. Long-term remission has often been considered unlikely, and a significant proportion of people with serious mental illness do not respond fully to medication at all. For these reasons, researchers are increasingly asking a different question: what if the root driver isn’t primarily neurotransmitter imbalance — but impaired brain energy?

The Chemical Imbalance Theory: An Incomplete Model

The idea that mental illness is caused by a “chemical imbalance” — particularly involving neurotransmitters like dopamine and serotonin — has been widely accepted for decades. However, this model has significant limitations. There is no consistent, measurable biomarker that confirms schizophrenia is caused by a simple neurotransmitter imbalance. While dopamine dysregulation is clearly involved in psychosis, the theory does not explain why this dysregulation occurs in the first place. Increasingly, researchers are recognising that the chemical imbalance model may be a downstream effect — not the root cause. And the evidence pointing elsewhere is growing rapidly.

The Metabolic Connection: Stronger Than We Realised

One of the most striking findings in recent research is how consistently serious mental illness and metabolic dysfunction appear together — even before medication is introduced. A 2026 expert consensus paper published in Frontiers in Nutrition, involving leading researchers including Dr. Christopher Palmer (Harvard), Dr. Shebani Sethi (Stanford), and six other specialists, highlighted these relationships with striking clarity:

 

3.7

More likely to have insulin resistance at first diagnosis of schizophrenia

3.5

More likely to have metabolic syndrome at first diagnosis of bipolar disorder

2.7

More likely to develop major depression with prediabetes-range blood glucose

These figures are not from people on long-term antipsychotic medication — they reflect metabolic dysfunction present at or near the time of first diagnosis. This strongly suggests that metabolic dysfunction is not simply a side effect of treatment, but may be fundamentally involved in the development of these conditions.

Insulin resistance is linked to cerebral glucose hypometabolism — a state where the brain struggles to use glucose efficiently as fuel. This has been observed in schizophrenia, bipolar disorder, and treatment-resistant depression, suggesting that for some individuals, the brain may be in a state of energy crisis long before a formal diagnosis is made.

A Shift Toward Metabolic Psychiatry

Researchers such as Dr. Christopher Palmer at Harvard Medical School are helping to pioneer a new perspective: that serious mental illnesses may, in part, be disorders of brain metabolism. This emerging field — metabolic psychiatry — focuses on how the brain produces and uses energy at a cellular level, and in particular, the role of the mitochondria: the structures responsible for generating energy within brain cells.

When mitochondrial function is impaired, the brain may struggle to regulate neural signalling, inflammation, oxidative stress, and neurotransmitter balance — creating a powerful link between metabolic dysfunction and psychiatric symptoms. Ketogenic metabolic therapy has been shown to decrease neuroinflammation, regulate neurotransmitter systems, reduce hyperexcitability of neural networks, stabilise neuronal firing rates, and improve brain energy metabolism. Ketogenic diets also promote mitochondrial biogenesis — the creation of new mitochondria — which may help restore brain function at a cellular level.

What Is a Ketogenic Diet?

A ketogenic diet is a high-fat, low-carbohydrate eating pattern that shifts the body away from burning glucose (sugar) for fuel, and toward producing ketones from fat instead. Foods typically include meat, fish, eggs, nuts, cheese, non-starchy vegetables, and healthy oils, while significantly reducing bread, pasta, rice, sugar, and most grains.

In a ketogenic state, the body produces ketones — an alternative fuel derived from fat — which may offer several advantages for brain function:

  • More stable energy delivery to the brain, bypassing impaired glucose metabolism
  • Increased mitochondrial efficiency and the creation of new mitochondria
  • Higher-quality ATP (cellular energy) production
  • Reduced neuroinflammation and oxidative stress
  • Improved GABA/glutamate balance, reducing abnormal neuronal firing

This shift in fuel source may create a more stable and supportive environment for brain function — particularly in individuals with underlying metabolic dysfunction.

What the Research Actually Shows

The evidence base is still emerging, but the volume and consistency of findings has grown substantially in recent years. Here is a comprehensive summary of the current clinical evidence.

Early Evidence (1965)

One of the earliest studies, Pacheco et al. (1965), involved 10 women with chronic schizophrenia placed on a ketogenic diet. Symptoms improved during the intervention and worsened when the diet was removed. This was one of the only early clinical investigations in this area, with very little follow-up research for decades — until more recent work began gaining traction in the 2010s and accelerating substantially through the 2020s.

Case Reports Showing Remission

Kraft & Westman (2009)

A 70-year-old woman with chronic schizophrenia experienced complete remission of hallucinations and delusions, sustained for over 12 months on a low-carbohydrate ketogenic diet.

Palmer (2017)

Two patients with schizoaffective disorder showed significant symptom reduction. Symptoms returned when the diet stopped and improved again when ketosis resumed — a compelling dose-response signal.

Palmer et al. (2019)

Two patients with schizophrenia achieved long-term remission — including one case lasting over 12 years without antipsychotic medication.

Laurent et al. (2025)

Two patients with schizoaffective disorder achieved full remission using validated clinical assessment tools (GAD-7, DASS-42, PCL-5, PHQ-9). The first patient — a 17-year-old with treatment-resistant illness — reported complete cessation of hallucinations, suicidal ideation, depression, and anxiety within 6 weeks, sustained over 24 weeks of follow-up.

Newiss (2025) — Carnivore Ketogenic Diet

A man with schizophrenia followed a carnivore ketogenic diet with nutritional therapy support. His mental health team confirmed his schizophrenia was in remission after nine months. He came off all psychiatric medications, his community treatment order was discharged, and he remained stable — with blood ketone levels consistently maintained between 1.0 and 5.0 mmol/L.

10+

Total participants documented across case reports showing improvement or remission

12+

Years of sustained remission in one documented case without antipsychotic medication

6

Weeks to full remission in one treatment-resistant case (Laurent et al., 2025)

A note on case report evidence

The published case reports in this area have consistently documented meaningful improvement or remission. That said, it is important to recognise that the current body of evidence is still in its early stages. Larger controlled trials are needed to determine true response rates across the broader population. Schizophrenia is also likely influenced by multiple interacting factors including genetics, environment, and trauma — and not every individual will respond to a metabolic approach.

Larger Clinical Data: Danan et al. (2022)

A retrospective analysis of 31 inpatients with severe, treatment-refractory mental illness — including major depressive disorder, bipolar disorder, and schizoaffective disorder — placed on a ketogenic diet in a psychiatric hospital setting. Among the 10 patients with schizoaffective disorder, PANSS scores (the gold-standard measure of psychotic symptoms) improved dramatically from an average of 91.4 down to 49.3 (p<0.001). Hamilton Depression Rating Scale scores across the broader group improved from 25.4 to 7.7. Critically, 64% of all participants were discharged on less psychiatric medication than when they were admitted — a finding with profound implications for quality of life and long-term medication burden.

Stanford Pilot Trial: Sethi et al. (2024)

The most rigorously designed study to date. Twenty-one adults with schizophrenia or bipolar disorder and existing metabolic dysfunction followed a ketogenic diet for four months while continuing their antipsychotic medications. Results were striking: 79% showed clinically meaningful psychiatric improvement. Participants who were fully adherent showed the greatest improvements, with some achieving what researchers described as a “recovered” clinical state. Metabolically, participants lost an average of 10% of body weight, reduced waist circumference by 11%, achieved a 27% reduction in insulin resistance, and a 25% drop in triglycerides. None of the participants met criteria for metabolic syndrome by the end of the trial — compared to 29% who did at the start.

 

✓ 2026 International Expert Consensus — Frontiers in Nutrition

In a landmark modified Delphi study published in February 2026, a panel of 47 mental health experts — including Dr. Christopher Palmer (Harvard), Dr. Shebani Sethi (Stanford), and leading researchers from Edinburgh, Duke, and Michigan — reached consensus agreement on all 33 clinical statements about ketogenic metabolic therapy (KMT) in serious mental illness. 100% of panellists agreed that KMT shows promise in treating serious mental illness. 97.9% agreed that ketogenic metabolic therapy should be considered as a potential option for suitable patients who wish to explore it. The consensus also confirmed that even individuals without visible signs of metabolic dysfunction may benefit, as metabolic dysfunction can be present in the brain even when peripheral markers appear normal.

A Growing RCT Pipeline

The field is now moving beyond case reports and pilot studies. A randomised placebo-controlled clinical trial is currently underway in Australia, enrolling 100 non-hospitalised adults with bipolar disorder, schizoaffective disorder, or schizophrenia, comparing a dietitian-led ketogenic diet against standard dietary guidelines over 14 weeks. This trial — the first properly powered RCT in this space — is measuring psychiatric outcomes, cognitive function, metabolic markers, sleep quality, and gut microbiome changes using wearable devices alongside standard clinical assessments.

Additionally, a randomised controlled trial published in JAMA Psychiatry in February 2026 assessed the ketogenic diet specifically for treatment-resistant depression — one of the most prestigious psychiatric journals in the world — signalling that metabolic psychiatry is now being taken seriously at the highest levels of mainstream medicine.

Who Might This Be Relevant For?

Based on the current evidence and the 2026 expert consensus, this research may be particularly relevant for individuals who are exploring complementary approaches alongside their existing mental health support. It may be especially relevant for those who:

  • Have not responded fully to medication alone, or are considered treatment-resistant
  • Are experiencing metabolic side effects from antipsychotic medications, such as weight gain or insulin resistance
  • Have a family history of both mental illness and metabolic conditions such as Type 2 diabetes
  • Show signs of metabolic dysfunction such as elevated blood sugar, high triglycerides, or central obesity
  • Are looking to complement their existing treatment with evidence-informed lifestyle and nutritional strategies
  • Decline, cannot access, or do not tolerate pharmaceutical treatments

Importantly, the 2026 consensus also noted that even individuals without visible signs of metabolic dysfunction may benefit — as metabolic issues in the brain can exist independently of what blood tests show.

 

Important Note on Medication

The research discussed in this article does not suggest anyone should reduce or discontinue antipsychotic medication without close supervision from their treating psychiatrist. In several of the case studies cited, dietary intervention was introduced alongside existing medication, with adjustments made gradually under medical supervision as symptoms improved. The 2026 expert consensus specifically states that psychiatric medication adjustments may be required during ketogenic therapy and must be managed by a prescribing clinician. Any dietary or lifestyle changes of this nature should always be discussed with your treating doctor first.

Is This a Proven Cure?

Not for every patient, and the researchers themselves are clear about this. The current evidence includes case reports, small case series, one retrospective inpatient study, and one pilot clinical trial. Large-scale randomised controlled trials are still needed and are now underway. Schizophrenia and psychosis are complex conditions, likely influenced by multiple interacting factors including genetics, environment, trauma, and metabolic health — and no single intervention is expected to work universally.

But the direction — and the momentum — is unmistakable. The long-held belief that schizophrenia is purely a lifelong, untreatable brain disorder is being meaningfully challenged by credible researchers at some of the world’s most respected institutions. The 2026 international expert consensus, involving Harvard, Stanford, Edinburgh, and Duke researchers, represents a significant watershed moment for this field.

What Does This Look Like in Practice?

For individuals and families interested in exploring metabolic approaches to mental health support, a practical starting point might include:

  • Speaking with your GP about insulin resistance, fasting glucose, and basic metabolic screening — including a fasting insulin test, which is not routinely ordered but highly informative
  • Working with a qualified dietitian experienced in therapeutic and low-carbohydrate nutrition
  • Reducing ultra-processed foods and refined sugars as a foundational first step, before committing to a full ketogenic approach
  • Exploring Dr. Christopher Palmer’s book Brain Energy, which outlines the metabolic theory of mental illness in accessible and well-referenced detail
  • Visiting MetabolicMind.org, a free resource for patients, families, and clinicians exploring metabolic approaches to mental health
  • Combining dietary changes with counselling and emotional wellbeing support — as the evidence consistently shows that holistic, multi-modal approaches produce the best outcomes

These are starting points — not prescriptions. The goal is to open a conversation with your treating team, not to replace professional care.

A New Direction for Mental Health

This doesn’t mean abandoning medication or conventional care. It means expanding the model. A more integrated future approach to serious mental illness may include metabolic assessment alongside psychiatric evaluation, nutritional interventions like ketogenic therapy as an adjunct to medication, lifestyle and therapeutic strategies targeting inflammation and mitochondrial health, and genuinely personalised treatment rather than one-size-fits-all pharmacology.

The question is no longer just: “How do we suppress symptoms?” But rather: “What if the brain is struggling to produce and regulate energy — and what happens when we address that?” For some individuals, emerging evidence suggests the answer may be far more powerful than we once believed.

 

Our Approach at Reconnect

At Reconnect Health Solutions, we take a holistic and person-centred approach to mental health support. We work closely with our accredited practising dietitians, who specialise in therapeutic nutritional approaches including anti-inflammatory and metabolic nutrition strategies. While we do not deliver ketogenic therapy as a standalone clinical treatment, we take seriously the growing evidence connecting metabolic health, nutrition, and mental wellbeing — and we’re here to support you in exploring every avenue. If you or someone you care about is navigating psychosis, schizophrenia, or related mental health challenges, we’d love to hear from you.

Disclaimer: This blog is intended for educational purposes only and does not constitute medical advice. The research discussed is emerging and should not be interpreted as a recommendation to alter any existing treatment plan. Please consult your GP or qualified mental health professional before making any changes to your care. Last reviewed: March 2026.

References

Danan, A., Westman, E. C., Saslow, L. R., & Ede, G. (2022). The ketogenic diet for refractory mental illness: a retrospective analysis of 31 inpatients. Frontiers in Psychiatry, 13, 951376. https://doi.org/10.3389/fpsyt.2022.951376
Ede, G., Bernstein, M., Calabrese, L., Campbell, I., Laurent, N., Palmer, C. M., Sethi, S., & Zupec-Kania, B. (2026). Awareness and best practices in using ketogenic therapy to treat serious mental illness: a modified Delphi consensus. Frontiers in Nutrition, 13, 1749406. https://doi.org/10.3389/fnut.2026.1749406
Gao, M., Kirk, M., Knight, H., Lash, E., et al. (2026). A ketogenic diet for treatment-resistant depression: a randomised clinical trial. JAMA Psychiatry. Published February 2026.
Kraft, B. D., & Westman, E. C. (2009). Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. Nutrition & Metabolism, 6(1), 10. https://doi.org/10.1186/1743-7075-6-10
Kucukgoncu, S., et al. (2019). Insulin resistance and metabolic abnormalities in patients with first-episode psychosis: a systematic review and meta-analysis. Psychological Medicine, 49(13), 2139–2147. https://doi.org/10.1017/S0033291718003366
Laurent, N., Bellamy, E. L., Tague, K. A., Hristova, D., & Houston, A. (2025). Ketogenic metabolic therapy for schizoaffective disorder: a retrospective case series of psychotic symptom remission and mood recovery. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2025.1506304
Longhitano, C., et al. (2024). The effects of ketogenic metabolic therapy on mental health and metabolic outcomes in schizophrenia and bipolar disorder: a randomised controlled clinical trial protocol. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2024.1444483
Newiss, G. (2025). Case report: remission of schizophrenia using a carnivore ketogenic metabolic therapy with nutritional therapy practitioner support. Frontiers in Nutrition, 12, 1591937. https://pmc.ncbi.nlm.nih.gov/articles/PMC12234327/
Pacheco, A., Easterling, W. S., & Pryer, M. W. (1965). A pilot study of the ketogenic diet in schizophrenia. American Journal of Psychiatry, 121(11), 1110–1111. https://doi.org/10.1176/ajp.121.11.1110
Palmer, C. M. (2017). Ketogenic diet in the treatment of schizoaffective disorder: two case studies. Schizophrenia Research. Available via PubMed.
Palmer, C. M., Gilbert-Jaramillo, J., & Westman, E. C. (2019). The ketogenic diet and remission of psychotic symptoms in schizophrenia: two case reports. Schizophrenia Research, 208, 439–440. https://doi.org/10.1016/j.schres.2019.03.013
Perry, B. I., et al. (2016). Insulin resistance, glucose, and lipid abnormalities in people with early psychosis: a systematic review and meta-analysis. The Lancet Psychiatry, 3(11), 1049–1058. https://doi.org/10.1016/S2215-0366(16)30272-9
Sethi, S., Wakeham, D., Ketter, T., Hooshmand, F., et al. (2024). Ketogenic diet intervention on metabolic and psychiatric health in bipolar and schizophrenia: a pilot trial. Psychiatry Research, 335, 115866. https://doi.org/10.1016/j.psychres.2024.115866

Sharing is Caring

Facebook
Twitter
LinkedIn

Submit An Enquiry